The global Alzheimer's disease diagnostic market is growing as healthcare providers invest in advanced diagnostic tools to support early detection and disease management. The market was valued at USD 10.26 billion in 2024 and is projected to reach USD 26.64 billion by 2035, growing at a CAGR of 9.02%.

The Alzheimer's Disease Diagnostic Market includes early onset Alzheimer's, late onset Alzheimer's, familial Alzheimer's disease, genetic testing, neurological exam, mini mental state exam, brain imaging, clinics, hospitals, diagnostic centers, and other diagnostic solutions.

Cognitive assessment holds the largest market share at 38% as it serves as a foundational methodology for initial diagnosis. This segment benefits from lower costs, faster implementation, and broad accessibility in clinical settings, making it the primary screening method for healthcare providers.

Neuroimaging is emerging as the fastest-growing application segment, driven by rising demand for precise diagnostic tools. Advanced imaging techniques like PET and MRI scans are considered essential for confirmatory diagnosis and monitoring disease progression.

Biomarker testing and genetic testing also contribute substantially to the market, though they occupy smaller portions of the overall landscape. Growth trends indicate a robust demand for diagnostic solutions supporting diverse scientific and clinical needs across various Alzheimer's disease types.

Eli Lilly and Company continues investing heavily in Alzheimer's biomarker and cognitive impairment research, supporting earlier disease detection strategies. The company's neurological R&D efforts contribute to increasing adoption of cognitive assessment tools.

Biogen Inc. maintains strong neuroscience and neurodegenerative disease research investments supporting hospital-based Alzheimer's diagnosis. Hospitals dominate with an estimated 42% share because they provide integrated neurological imaging, biomarker testing, and specialist consultation.

The future market will depend on technological advancements in diagnostic tools, increasing prevalence of Alzheimer's disease, growing awareness and education, increased government funding and support, and aging population and demographic shifts.

FAQs

Q1. Why does cognitive assessment dominate the Alzheimer's disease diagnostic market?
Cognitive assessment dominates due to its foundational role in initial diagnosis, lower costs, faster implementation, and broad accessibility.

Q2. What is driving the growth of neuroimaging?
Rising demand for precise diagnostic tools and advanced imaging techniques like PET and MRI scans are driving neuroimaging adoption.

Tags: Alzheimer's disease diagnostic market, cognitive assessment, neuroimaging, biomarker testing, genetic testing